Ocutronics had developed and patented new technology for retinal imaging or "fundus" cameras. Its technology allows its camera to be the lowest cost on the market (by a factor of four) while providing significant product advantages. The camera is used for diagnosis of diabetic retinopathy, a condition that 80% of the nation's 23.6 diabetics will get.
Our camera is non-mydriatic so that patients' eyes do not need to be dilated. Due to our patented optics it takes very high resolution pictures through only 2mm of pupil diameter versus 3.85mm claimed by others. It is very small and portable and does not need a fixed installation like other expensive fundus cameras.
Because only 50% of diabetics are compliant in getting annual eye exams, the federal government's HEDIS has changed the standard of care from one fundus photograph per year by an eye care physician to one per year by a primary care physician. Traditional fundus cameras are not appropriate for primary care physicians due to cost, complexity and size. Ocutronics will provide at little or no cost its very low cost, easy to use, portable camera to primary care and eye care physicians and receive payment on a cost-per-use basis.
The market for fundus photographs in the U.S. is approximately $1.75 Billion and growing as diabetes grows. In the U.S. there are 23.6 million diabetics (8% of the U.S. population), growing by 1.5 million new cases each year.
Ocutronics' camera's unique design simplifies the optical system allowing it to be manufacturered for a small fraction of the cost of other cameras.
The unique design also allows it to operate through only 2mm of pupil diameter with a 45 degree field of vision while industry leaders with much more expensive cameras require a minimum of 3.85mm of pupil diameter for only a 30 degree field of vision.